IMS Capital Management’s Biogen BIIB Stock Holding History

IMS Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-108	Closed	-$38K	–	150
2018 Q3	$38K	Buy	+108	New	+$37.2K	0.03%	212

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

IMS Capital Management's BIIB Position: Q4 2018 in Review

IMS Capital Management sold out of Biogen (BIIB) in Q4 2018, closing a stake of 108 shares — an estimated $38K sold.

IMS Capital Management first reported a position in BIIB in Q3 2018 and held it in 1 quarter. The position peaked at $38K in Q3 2018. 1,140 funds tracked by Wall St. Rank hold BIIB as of Q4 2018.

IMS Capital Management reported no remaining Biogen position as of Q4 2018 after selling out during the quarter.
IMS Capital Management sold 108 Biogen shares in Q4 2018, an estimated $38K.
IMS Capital Management first reported a position in Biogen in Q3 2018 and held it in 1 quarter.
IMS Capital Management's Biogen position peaked at $38K in Q3 2018.
1,140 funds tracked by Wall St. Rank held Biogen as of Q4 2018.

Based on IMS Capital Management's 13F filing for Q4 2018, filed 7 Feb 2019.